Physician profile
Heather Bunch
NPI 1447942479
$3,443.06
in general payments reported to CMS, 2019-2025
22 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $103 · 2024: $1,785 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415 · Travel and Lodging: $933 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.03 |
| Travel and Lodging | $933.04 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,707.77 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $546.98 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $204.94 | 2023-2025 | |
| Lilly USA, LLC | $155.88 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $142.98 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.14 | 2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $78.55 | 2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $64.97 | 2024-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $54.29 | 2024 | |
| Phathom Pharmaceuticals, INC. | $44.12 | 2023-2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $43.37 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $40.39 | 2025 | |
| Daiichi Sankyo INC. | $38.26 | 2024 | Injectafer |
| Dexcom, INC. | $33.92 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $32.58 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $26.12 | 2024 | Gemtesa |
| Amgen INC. | $23.81 | 2024 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $18.76 | 2024 | Strensiq |
| Exact Sciences Corporation | $18.61 | 2024 | Cologuard Collection Kit |
| Axonics, INC. | $16.69 | 2023 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $16.25 | 2025 | Gattex |
| Esperion Therapeutics, INC. | $15.68 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.